Mapping an emerging framework for regenerative medicine reimbursement
To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.
EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.
You can now read the lay summary for the article entitled 'The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics' from Aurélie Mahalatchimy & Alex Faulkner .
The development of regenerative medicines (RMs) carry substantial risks for companies because production costs are often large and products are yet to show effective long-term results. A broad examination of published literature in the field of RM shows there is a growing discussion about policies that aim to encourage the development of RMs through risk-sharing policies. Interviews with numerous organisations in the field of RM showed that trade associations are the most active in considering ways to structure financial reimbursement for the RM industry.
What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here:
The full original article can be accessed here:
 Mahalatchimy A, Faulkner A. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics. Regen. Med. 12(6), 611–622 (2017).